Viridian Therapeutics, Inc.
USD18.56
+0.53 (+2.94%)
CEO
Stephen F. Mahoney
IPO Date
2014-06-18
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$18.17
Prev. Close
$18.03
Day Low
$18.14
Day High
$19.23
52W Low
$13.18
52W High
$34.29
Market Cap
$1.67B
Volume
2.15M
| 32,341 |
| $18.48 |
| 2 Jul 2026 | Moses Jennifer K. | director | A-Award | Acquired | 32,341 | $18.48 |
| 2 Jul 2026 | Gheuens Sarah | director | A-Award | Acquired | 32,341 | $18.48 |
| 2 Jul 2026 | Kiselak Tomas | director | A-Award | Acquired | 32,341 | $18.48 |
| 2 Jul 2026 | Morris Arlene | director | A-Award | Acquired | 32,341 | $18.48 |
| 13 May 2026 | Fairmount Funds Management LLC | director, 10 percent owner: | P-Purchase | Acquired | 1,176,470 | $17.00 |
| 9 Mar 2026 | Harmon Seth | Chief Financial Officer | F-InKind | Disposed | 2,031 | $30.19 |
| 9 Mar 2026 | Beetham Thomas W. | Chief Operating Officer | F-InKind | Disposed | 3,048 | $30.19 |
| 9 Mar 2026 | Tousignant Jennifer | Chief Legal Officer | F-InKind | Disposed | 1,675 | $30.19 |